Rhumbline Advisers Boosts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Rhumbline Advisers increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 7.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,189 shares of the company’s stock after purchasing an additional 4,600 shares during the period. Rhumbline Advisers owned 0.10% of Vera Therapeutics worth $1,518,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in VERA. New York State Common Retirement Fund raised its holdings in shares of Vera Therapeutics by 19.5% during the 4th quarter. New York State Common Retirement Fund now owns 28,822 shares of the company’s stock worth $1,219,000 after acquiring an additional 4,709 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Vera Therapeutics by 5.9% during the 4th quarter. Bank of New York Mellon Corp now owns 141,948 shares of the company’s stock worth $6,003,000 after acquiring an additional 7,895 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Vera Therapeutics by 19.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 430,665 shares of the company’s stock worth $18,213,000 after acquiring an additional 68,860 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Vera Therapeutics by 515.0% during the 4th quarter. Victory Capital Management Inc. now owns 235,267 shares of the company’s stock worth $9,949,000 after acquiring an additional 197,014 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Vera Therapeutics by 22.9% during the 4th quarter. Arizona State Retirement System now owns 12,586 shares of the company’s stock worth $532,000 after acquiring an additional 2,348 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Price Performance

Shares of VERA stock opened at $20.92 on Thursday. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61. The stock’s 50-day moving average is $22.54 and its 200 day moving average is $30.17. The company has a market cap of $1.33 billion, a P/E ratio of -6.97 and a beta of 1.13. The company has a debt-to-equity ratio of 0.10, a current ratio of 27.68 and a quick ratio of 27.68.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same quarter in the prior year, the company earned ($0.56) earnings per share. Research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on VERA. Scotiabank reissued an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Wedbush cut their target price on Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 7th. Guggenheim reissued a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price objective (up previously from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Finally, Cantor Fitzgerald cut their price objective on Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $65.00.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.